Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

First Case of Emergence of Atovaquone Resistance in Plasmodium falciparum during Second-Line Atovaquone-Proguanil Treatment in South America

Eric Legrand, Magalie Demar, Béatrice Volney, Marie-Thérèse Ekala, Marc Quinternet, Christiane Bouchier, Thierry Fandeur, Christophe Rogier, Bernard Carme, Odile Mercereau Puijalon, Philippe Esterre
Eric Legrand
Centre National de Référence sur la Chimiorésistance du Paludisme dans la région Antilles-Guyane Institut Pasteur de la Guyane BP 6010 F-97306 Cayenne-Cedex, French Guiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: elegrand@pasteur-cayenne.fr
Magalie Demar
Laboratoire Hospitalo-Universitaire de Parasitologie et Mycologie Faculté de Médecine Antilles-Guyane et Centre Hospitalier de Cayenne Equipe EA 3593 Cayenne, French Guiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Béatrice Volney
Centre National de Référence sur la Chimiorésistance du Paludisme dans la région Antilles-Guyane Institut Pasteur de la Guyane BP 6010 F-97306 Cayenne-Cedex, French Guiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Thérèse Ekala
Unité d'Immunologie Moléculaire des Parasites CNRS URA 2581 Institut Pasteur 25 rue du Docteur Roux 75724 Paris Cedex 15, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Quinternet
Centre National de Référence sur la Chimiorésistance du Paludisme dans la région Antilles-Guyane Institut Pasteur de la Guyane BP 6010 F-97306 Cayenne-Cedex, French Guiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Bouchier
Pasteur Genopole Ile de France Institut Pasteur 25 rue du Docteur Roux 75724 Paris Cedex 15, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Fandeur
Faculté de Pharmacie UFR sciences pharmaceutiques UMR INRA-Université d'Immunologie Parasitaire et de Vaccinologie Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christophe Rogier
Unité de recherche en Biologie et Epidémiologie Parasitaire Institut de Medecine Tropicale du Service de Santé des Armées Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Carme
Laboratoire Hospitalo-Universitaire de Parasitologie et Mycologie Faculté de Médecine Antilles-Guyane et Centre Hospitalier de Cayenne Equipe EA 3593 Cayenne, French Guiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Odile Mercereau Puijalon
Unité d'Immunologie Moléculaire des Parasites CNRS URA 2581 Institut Pasteur 25 rue du Docteur Roux 75724 Paris Cedex 15, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Esterre
Centre National de Référence sur la Chimiorésistance du Paludisme dans la région Antilles-Guyane Institut Pasteur de la Guyane BP 6010 F-97306 Cayenne-Cedex, French Guiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01532-06
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

The atovaquone-proguanil combination (Malarone) has been introduced in French Guiana for prophylaxis and second-line treatment for Plasmodium falciparum malaria in 2002. We report here a treatment failure in a patient who was given a second-line atovaquone-proguanil treatment. A nonimmune P. falciparum patient was infected during a 5-day visit without prophylaxis in Maripasoula, a region of malaria endemicity, and while residing in a malaria-free area, the patient experienced three malaria episodes on day 0 (treated with halofantrine [Halfan]), day 25 (treated with atovaquone-proguanil), and day 49 (treated with quinine-doxycline). All treatments were well tolerated. Plasma atovaquone concentration, measured 1 day after atovaquone-proguanil administration, was 1.45 μg/ml, indicating adequate drug absorption (8).

In vitro susceptibility tests, performed on blood samples from day 0 and day 49 (no blood sample was collected before atovaquone-proguanil administration), showed an increased 50% inhibitory concentration (IC50) value for atovaquone on day 49 compared to that on day 0 (Table 1). Genotyping of the parasites from days 0, 26, and 49, using four microsatellite loci (C4M69, 7A11, C4M79, and Pf2802) (1), msp2, and glurp (6), showed identical alleles for each locus in the three samples. The sequencing of cyt b, the atovaquone target (4, 9, 11), showed a wild-type 268 codon in the day 0 and day 26 samples and a 268S mutation in the day 49 sample. The sequencing of Pfdhfr-ts (the target of proguanil) (3) showed the same C50R N51I S108N triple mutant in the three samples, which furthermore had an increased copy number (two gene copies). In brief, the parasite genotypes of the three episodes were indistinguishable for all loci except cyt b. These data indicate that the second and third episodes were recrudescences due to successive treatment failures.

The day 49 parasites presented elevated IC50 levels for atovaquone and a 268S mutant Cyt b, a mutation consistently associated with in vitro resistance to atovaquone and therapeutic failures (2, 4, 5, 8, 10). The resistance mutation was undetected in both pretreatment samples, indicating the emergence of resistant parasites during the course of the atovaquone-proguanil treatment. The presence of the 268S cyt b mutation was associated with a significantly lower IC50 level for atovaquone than for some atovaquone-proguanil treatment failures associated with the same mutation (2, 8). This result may suggest, in light of lack of cyt b mutation in an atovaquone-proguanil failure (12), additional targets for atovaquone-proguanil. However, a similar moderate increase in IC50 has been reported for recrudescent isolates from Thai patients treated with atovaquone-proguanil (7). Both in Thailand and in French Guiana, therapeutic failure may involve reduced susceptibility to both proguanil and atovaquone. In vitro resistance to cycloguanil, the major metabolite of proguanil, is very high in French Guiana (close to 100% prevalence in 2000 with a mean IC50 of >4,100 nM). The mutant Pfdhfr-ts and cyt b genotypes observed in our atovaquone-proguanil therapeutic failure are consistent with combined resistance to both proguanil and atovaquone.

The observation of this first indigenous case of atovaquone-proguanil treatment failure in South America, due to drug resistance, shows the need for increased vigilance in the follow-up of patients treated with atovaquone-proguanil and in the reinforced surveillance of the parasite population.

View this table:
  • View inline
  • View popup
TABLE 1.

In vitro drug susceptibility profiles of the day 0 and day 49 parasitesa

ACKNOWLEDGMENTS

This project was supported by the French Ministry of Health (InVS agency, Paris) and the EU commission-funded program RESMALCHIP (QLK2-CT-2002-01503).

We thank B. Maubert (Biomedical Unit, Institut Pasteur de la Guyane, Cayenne, French Guiana) for providing the blood samples.

  • Copyright © 2007 American Society for Microbiology

REFERENCES

  1. 1.↵
    Bogreau, H., F. Renaud, H. Bouchiba, P. Durand, S.-B. Assi, M.-C. Henry, E. Garnotel, B. Pradines, T. Fusai, B. Wade, E. Adehossi, P. Parola, M. Ali Kamil, O. Mercereau-Puijalon, and C. Rogier. 2006. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Am. J. Trop. Med. Hyg.74:953-959.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Fivelman, Q. L., G. A. Butcher, I. S. Adagu, D. C. Warhurst, and G. Pasvol. 2002. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate Lagos, Nigeria. Mal. J.1:1-4.
    OpenUrlCrossRef
  3. 3.↵
    Foote, S. J., D. Galatis, and A. F. Cowman. 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA87:3014-3017.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Korsinczky, M., N. Chen, B. Kotecka, A. Saul, K. Rieckmann, and Q. Cheng. 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother.44:2100-2108.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Kuhn, S., M. J. Gill, and K. C. Kain. 2005. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune North American traveller to West Africa. Am. J. Trop. Med. Hyg.72:407-409.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Legrand, E., B. Volney, A. Lavergne, C. Tournegros, L. Florent, D. Accrombessi, M. Guillotte, O. Mercereau-Puijalon, and P. Esterre. 2005. Molecular analysis of two local falciparum malaria outbreaks on the French Guiana coast confirms the msp1 B-K1/varD genotype association with severe malaria. Mal. J.4:26.
    OpenUrlCrossRef
  7. 7.↵
    Looareesuwan, S., C. Viravan, H. K. Webster, D. E. Kyle, D. B. Hutchinson, and C. K. Canfield. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg.54:62-66.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Musset, L., B. Pradines, D. Parzy, R. Durand, P. Bigot, and J. Le Bras. 2006. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J. Antimicrob. Chemother.57:110-115.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Sabchareon, A., P. Attanath, P. Phanuaksook, P. Chanthavanich, Y. Poonpanich, D. Mookmanee, T. Chongsuphajaisiddhi, B. M. Sadler, Z. Hussein, C. J. Canfield, and D. B. A. Hutchinson. 1998. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg.92:201-206.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Schwöbel, B., M. Alifrangis, A. Salanti, and T. Jelinek. 2003. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Mal. J.2:1-7.
    OpenUrlCrossRef
  11. 11.↵
    Srivastava, I., H. Rottenberg, and A. Vaidya. 1997. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem.272:3961-3962.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Wichmann, O., M. Muehlen, H. Gruss, F. P. Mockenhaupt, N. Suttorp, and T. Jelinek. 2004. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Mal. J.3:1-3.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
First Case of Emergence of Atovaquone Resistance in Plasmodium falciparum during Second-Line Atovaquone-Proguanil Treatment in South America
Eric Legrand, Magalie Demar, Béatrice Volney, Marie-Thérèse Ekala, Marc Quinternet, Christiane Bouchier, Thierry Fandeur, Christophe Rogier, Bernard Carme, Odile Mercereau Puijalon, Philippe Esterre
Antimicrobial Agents and Chemotherapy May 2007, 51 (6) 2280-2281; DOI: 10.1128/AAC.01532-06

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
First Case of Emergence of Atovaquone Resistance in Plasmodium falciparum during Second-Line Atovaquone-Proguanil Treatment in South America
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
First Case of Emergence of Atovaquone Resistance in Plasmodium falciparum during Second-Line Atovaquone-Proguanil Treatment in South America
Eric Legrand, Magalie Demar, Béatrice Volney, Marie-Thérèse Ekala, Marc Quinternet, Christiane Bouchier, Thierry Fandeur, Christophe Rogier, Bernard Carme, Odile Mercereau Puijalon, Philippe Esterre
Antimicrobial Agents and Chemotherapy May 2007, 51 (6) 2280-2281; DOI: 10.1128/AAC.01532-06
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ACKNOWLEDGMENTS
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antimalarials
Atovaquone
drug resistance
Malaria, Falciparum
Plasmodium falciparum
proguanil

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596